
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

**Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934**

For the month of January 2023

Commission File Number: 001-36349

MediWound Ltd.

(Translation of registrant's name into English)

**42 Hayarkon Street
Yavne, 8122745 Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1): ___

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7): ___

CONTENTS

On January 9, 2023, MediWound Ltd. (the “**Company**”) made a presentation at the J.P. Morgan 41st Annual Healthcare Conference, highlighting its clinical products, and providing certain updates regarding the results of clinical trials, as well as certain estimates and projections as to expected future financial results. Materials used in conjunction with the presentation are available on the Company’s website at www.mediwound.com and are furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this “**Form 6-K**”). The contents of the foregoing website are not a part of this Form 6-K.

The information contained in the presentation was provided as of January 9, 2023, and the Company does not undertake any obligation to update the presentation in the future or to update forward-looking statements to reflect subsequent actual results. The furnishing of the materials related to the presentation is not an admission as to the materiality of any information contained in those materials.

The contents of this Form 6-K (including the information contained in Exhibit 99.1) are hereby incorporated by reference into the Company’s Registration Statements on Form S-8, filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 and August 9, 2022 (Registration Nos. 333-195517, 333-210375, 333-223767, 333-195517, 333-210375, 333-230487, 333-236635, 333-255784, and 333-266697, respectively), and Form F-3, filed with the SEC on May 25, 2022 (Registration No. 333-265203).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MEDIWOUND LTD.

Date: January 9, 2023

By: /s/ Boaz Gur-Lavie
Name: Boaz Gur-Lavie
Title: Chief Financial Office

EXHIBIT INDEX

The following exhibit is furnished as part of this Form 6-K:

<u>Exhibit</u>	<u>Description</u>
99.1	Presentation of MediWound Ltd. for the 41st Annual J.P. Morgan Healthcare Conference entitled "Non-Surgical Biological Solutions for Tissue Repair & Regeneration" dated January 2023.



Non-Surgical Biological Solutions for Tissue Repair & Regeneration

January 2023 | Nasdaq: MDWD

Cautionary Note Regarding Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws, including but not limited to the statements related to the commercial potential of our products and product candidates, the anticipated development progress of our products and product candidates, and our expected cash runway. In some cases, you can identify forward-looking statements by terminology such as "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "predict," "potential," or the negative of these terms or other similar expressions. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Important factors that could cause such differences include, but are not limited to the uncertain, lengthy and expensive nature of the product development process; market acceptance of our products and product candidates; the timing and conduct of our studies of our product candidates; our ability to obtain marketing approval of our products and product candidates in the U.S. or other markets; our expectations regarding future growth, including our ability to develop new products; risks related to our contracts with BARDA; our ability to maintain adequate protection of our intellectual property; competition risks; and the need for additional financing. These and other significant factors are discussed in greater detail in MediWound's annual report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission ("SEC") on March 17, 2022, and other filings with the SEC from time-to-time. These forward-looking statements reflect MediWound's current views as of the date hereof and MediWound undertakes, and specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in their respective views or events or circumstances that occur after the date of this release except as required by law.

Certain studies and data presented herein have been conducted for us by other entities as indicated where relevant. Intellectual property, including patents, copyrights or trade secret displayed in this presentation, whether registered or unregistered, are the intellectual property rights of MediWound. MediWound's name and logo and other MediWound product names, slogans and logos referenced in this presentation are trademarks of MediWound Ltd. and/or its subsidiaries, registered in the U.S.A., EU member states and Israel.

NexoBrid development has been supported in part with federal funding from U.S. Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), within the U.S. Department of Health and Human Services (HHS), under ongoing USG Contract numbers HHSO100201500035C and HHSO100201800023C. Contract number HHSO100201500035C provides funding and technical support for the pivotal U.S. Phase 3 clinical study (DETECT) and the marketing approval registration process for NexoBrid as well as its procurement and availability under the expanded access treatment protocol (NEXT) in the U.S. Additional projects for evaluation of NexoBrid funded under the BARDA contract include randomized, controlled pivotal clinical trial for use in pediatric population, establishment of a pre-emergency use data package and development of the health economic model to evaluate the cost savings impact to enable market adoption in the United States.

We maintain our books and records in U.S. dollars and report under IFRS.

Company Highlights



Validated enzymatic
technology platform

FDA/EMA/PMDA approvals
14 successful clinical trials
120+peer reviewed publications



Diversified
portfolio

NexoBrid® - 2022 revenues: \$26-27M
EscharEx® - **\$2B*** opportunity



cGMP certified sterile
manufacturing facility

Provides capacity to scale
revenue growth



Global strategic
collaborations

BARDA, Vericel, DoD (US),
Kaken (JP), BSV (IN)



Solid balance sheet
& strong investor base

\$42M cash
Runway through 2025

*TAM - targeted addressable market; Source: Oliver Wyman market research

Leadership Team



Nachum (Homí) Shamir
Chairman of the Board

Luminex

GI·EN
IMAGING

Kodak



Ofer Gonen
Chief Executive Officer

gamida **Cell**

CACTUS

CBI



Prof. Lior Rosenberg
Founder, Medical Director

Ben-Gurion University
of the Negev

ISBI

EMA



Dr. Ety Klingler
Chief R&D Officer

teva

PROTEO
LOGICS

TEL AVIV
UNIVERSITY



Tzvi Palash
Chief Operating Officer

gamida **Cell**

PROTALIX
Biotherapeutics

Johnson & Johnson



Boaz Gur-Lavie
Chief Financial Officer

Abbott
A Promise for Life

MDCLONE

Pluristem



Dr. Robert J. Snyder
Chief Medical Officer

Systemix

3M

Johnson & Johnson

Proprietary Enzymatic Technology Platform

Clinically and commercially validated protein-based therapies



1
Pineapple stem harvest



2
Protein extraction




3
Purification, enrichment, stabilization



4
Complex mixture of proteolytic enzymes

Images modified from Labster theory and bioinfo

Selective enzymes target only non-viable tissue



Viable tissues preserved; healing begins



Multibillion Dollar Portfolio

Commercial

NexoBrid®

Disruptive therapy for burn care



Indication: Eschar removal of deep partial and full thickness burns

Classification: Orphan biological drug

Target users: Hospitalized patients

Substantial U.S. government support

Development status: FDA/EU/JP approved

TAM* (U.S.): **>\$200M**

Pipeline

EscharEx®

Next-gen enzymatic therapy for wound care**



Indication: Debridement of chronic / hard-to-heal wounds

Classification: Biological drug

Optimized for outpatient setting


Development status: Phase III ready

TAM* (U.S.): **>\$2B**

Pipeline

MW005

Biotherapy for non-melanoma skin cancers**



Indication: Treatment of non-melanoma skin cancers

Classification: Biological drug


Optimized for outpatient setting

Development status: Phase I/II

TAM* (U.S.): **>\$1B**

*TAM - targeted addressable market; Source: Oliver Wyman market research
**Investigational drug

Upcoming Milestones



Financial Highlights



BALANCE SHEET

\$42M in cash* as of
December 31, 2022
Cash runway - through 2025
Strong investor base



REVENUES

2022 revenues of **~\$26-27M**
NexoBrid is profitable
2023 Product revenues
>75% growth
2023 Product **gross margin >50%**;
scale-up drives further increase



COMMERCIALIZATION

Global expansion via strategic
collaborations (Vericel, Kaken, BSV, GAG)
Up to **\$211M** support by BARDA
EU direct sales force
(CAGR >20%)



ANALYSTS:

- Josh Jennings, MD, Cowen
- Jacob Hughes, Wells Fargo
- Francois Brisebois, Oppenheimer
- Swayampakula Ramakanth, PhD, HCW
- David Bouchey, Aegis
- Jason McCarthy, Ph.D, Maxim

* Cash, cash equivalents and short-term bank deposits; cash amount takes into account the receipt of \$7.5M milestone from Vericel upon BLA approval

NexoBrid[®]

Early, effective and selective non-surgical
eschar removal for severe burns


Validated & commercialized

Globally approved: FDA, EU, JP, IN; 11,000 patients

 MediWound

Clear Unmet Need for **Early, Effective and Selective Non-Surgical Eschar Removal** in Severe Burns

Eschar Removal is the **1st Critical Step in Burn Care**




Prevents local infection and sepsis

Avoids further deterioration and scarring

Enables initiation of wound healing

Allows visual assessment of wound bed

Current Practice* is **Traumatic & non-selective**



Loss of healthy tissue & blood

Challenging in delicate areas

Requires surgical team, operating room

NexoBrid®



Indicated for eschar removal of deep-partial & full-thickness thermal burns

Disruptive Bioactive Therapy for Burn Care

Significantly reduces need for surgery & improves patient outcomes



A sterile mixture of proteolytic enzymes

Effectively removes eschar within 4 hours without harming viable tissue or blood loss


Allows for early visual assessment of the wound




Easy-to-use, topical application at patient's bedside

NexoBrid® - Phase III Studies Demonstrate Superiority


Incidence of complete eschar removal




Time to complete eschar removal



Incidence of surgical eschar removal



Blood loss



No safety issues after 24 month follow-up

Non-inferiority in time to complete wound closure & scarring

Consistent with EU Phase III study & pediatrics Phase III study



EscharEx[®] Next-Generation Enzymatic Debridement for Wound Care

Superior to SOC -
Sets a new bar for efficacy

Targets **\$2b market
opportunity**

De-risked: based on a
validated technology

Approaches in Chronic Wound Debridement are abundant but sub-optimal



EscharEx[®]



Indicated for debridement of chronic and hard-to-heal wounds

Next-Generation Enzymatic Debridement - Wound Bed Preparation within a Week




VLU

DFU



- Investigational drug containing a sterile mixture of proteolytic enzymes
- Debrides chronic wounds in 4-6 daily applications
- Inline with current treatment workflows and reimbursement landscape
- Easy to use, daily topical application for outpatient setting
- Extended IP protection

EscharEx® Phase II Studies - Highly Efficacy vs. SOC

Primary Endpoint



EscharEx vs. Non-Surgical SOC




Current enzymatic treatment has limited efficacy and is slow acting


EscharEx® No safety issues | Consistent with two additional phase II studies

EscharEx® U.S. Market Opportunity

Market potential growth



2022 Epidemiology Estimate



Cost of treatment: 1,500-1,800\$*

EscharEx® anticipated to draw share from all other debridement modalities

MW005

Novel biotherapy for Non-Melanoma Skin Cancer

Effective and safe topical application

BCC is the most diagnosed skin cancer in the US

MW005



Novel Biotherapy for Non-Melanoma Skin Cancer




The Market

- 4.3M annual cases of Basal Cell Carcinomas diagnosed in the US
- Surgery is the SOC; topical products have high AEs & recurrence rates

The Product

- Investigational drug containing a sterile mixture of proteolytic enzymes
- Easy to use, high potency, 5-7 topical applications
- US Phase I/II study, demonstrated efficacy, safety and tolerability

Why MediWound?



* Cash amount takes into account the receipt of \$7.5M milestone from Vericel upon BLA approval